Salvatore Mazzeo, MD, PhD, Vita-Salute San Raffaele University, Milan & AOU Careggi, Florence, Italy, discusses the prognostic accuracy of blood-based biomarkers neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated-tau181 (p-tau181), evidenced in the PREVIEW study that aims to predict Alzheimer’s disease (AD) onset in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Patients were classified based on the presence or absence of AD pathology, as indicated by cerebrospinal fluid (CSF) biomarkers. The blood-based biomarkers were capable of identifying underlying AD pathology with high precision, with NfL performing particularly well in this early-stage population. Notably, rate of NfL change was able to predict the progression of cognitive decline. Measuring changes in plasma NfL concentration in earlier phases of neurodegeneration may be pivotal, in order to accurately guide decision making for SCD and MCI patients. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
